Jerome Lipper Multiple Myeloma Center, Division of Hematologic Malignancy, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Clin Cancer Res. 2015 Jun 15;21(12):2660-2. doi: 10.1158/1078-0432.CCR-14-3190. Epub 2015 Apr 15.
CD38 is a type II transmembrane glycoprotein that is highly expressed in multiple myeloma and is a promising target for immunotherapy. Daratumumab is a human monoclonal antibody that has potent anti-multiple myeloma activity both as monotherapy and in combination with other multiple myeloma treatments, and has breakthrough designation on this basis.
CD38 是一种 II 型跨膜糖蛋白，在多发性骨髓瘤中高度表达，是免疫治疗的一个有前途的靶点。达雷妥尤单抗是一种人源化单克隆抗体，无论是单药治疗还是与其他多发性骨髓瘤治疗联合使用，都具有强大的抗多发性骨髓瘤活性，并因此获得了突破性疗法的认定。
